Therapeutic response in feline Sandhoff disease despite immunity to intracranial gene therapy

Molecular Therapy

Volumn 21, Issue 7, 2013, Pages 1306-1315

  Bradbury, Allison M ^a   Cochran, J Nicholas ^a   McCurdy, Victoria J ^a   Johnson, Aime K ^a   Brunson, Brandon L ^a   Gray Edwards, Heather ^a   Leroy, Stanley G ^b   Hwang, Misako ^a   Randle, Ashley N ^a   Jackson, Laura S ^a   Morrison, Nancy E ^a   Baek, Rena C ^c   Seyfried, Thomas N ^c   Cheng, Seng H ^d   Cox, Nancy R ^a   Baker, Henry J ^a   Cachón González, M Begona ^e   Cox, Timothy M ^e   Sena Esteves, Miguel ^b   Martin, Douglas R ^a  

^a AUBURN UNIVERSITY   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c BOSTON COLLEGE   (United States)

^d GENZYME CORPORATION   (United States)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA N ACETYLHEXOSAMINIDASE; BETA N ACETYLHEXOSAMINIDASE ALPHA CHAIN; BETA N ACETYLHEXOSAMINIDASE BETA CHAIN; COMPLEMENTARY DNA; PARVOVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CAT; CONTROLLED STUDY; ENZYME ACTIVITY; HUMORAL IMMUNITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; SANDHOFF DISEASE; THALAMUS; VIRAL GENE THERAPY;

FELIDAE; MUS;

EID: 84879693104     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.86     Document Type: Article

References (49)

1. Gravel, RA, Clarke, JTR, Kaback, MM, Mahuran, D, Sandhoff, K and Suzuki, K (1995). The GM2 gangliosidoses. In: Scriver, CR, Beaudet, AL, Sly, WS and Valle, D (eds). The Metabolic and Molecular Bases of Inherited Disease, 7th edn., vol. 2. McGraw-Hill, Inc.: New York. pp. 2839-2879.
2. Tay, W (1881). Symmetrical changes in the region of the yellow spot in each eye of an infant. Tran Ophthalmol Soc UK 1: 155-157.
3. Arf, A, Bourgoin, C, Basso, L, Emiliani, C, Tancini, B, Chigorno, V et al. (2005). Bicistronic lentiviral vector corrects beta-hexosaminidase defciency in transduced and cross-corrected human Sandhoff fbroblasts. Neurobiol Dis 20: 583-593. (Pubitemid 41476284)
4. Guidotti, JE, Mignon, A, Haase, G, Caillaud, C, McDonell, N, Kahn, A et al. (1999). Adenoviral gene therapy of the Tay-Sachs disease in hexosaminidase A-defcient knock-out mice. Hum Mol Genet 8: 831-838. (Pubitemid 29189050)
5. Itakura, T, Kuroki, A, Ishibashi, Y, Tsuji, D, Kawashita, E, Higashine, Y et al. (2006). Ineffciency in GM2 ganglioside elimination by human lysosomal beta-hexosaminidase beta-subunit gene transfer to fbroblastic cell line derived from Sandhoff disease model mice. Biol Pharm Bull 29: 1564-1569. (Pubitemid 44166352)
6. Schwarze, SR, Ho, A, Vocero-Akbani, A and Dowdy, SF (1999). In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285: 1569-1572. (Pubitemid 29420581)
7. Cachón-González, MB, Wang, SZ, Lynch, A, Ziegler, R, Cheng, SH and Cox, TM (2006). Effective gene therapy in an authentic model of Tay-Sachs-related diseases. Proc Natl Acad Sci USA 103: 10373-10378. (Pubitemid 44051174)
8. Cachón-González, MB, Wang, SZ, McNair, R, Bradley, J, Lunn, D, Ziegler, R et al. (2012). Gene transfer corrects acute GM2 gangliosidosis-potential therapeutic contribution of perivascular enzyme fow. Mol Ther 20: 1489-1500.
9. Cork, LC, Munnell, JF, Lorenz, MD, Murphy, JV, Baker, HJ and Rattazzi, MC (1977). GM2 ganglioside lysosomal storage disease in cats with beta-hexosaminidase defciency. Science 196: 1014-1017. (Pubitemid 8106059)
10. Baker, HJ, Reynolds, GD, Walkley, SU, Cox, NR and Baker, GH (1979). The gangliosidoses: comparative features and research applications. Vet Pathol 16: 635-649. (Pubitemid 10204942)
11. Martin, DR, Krum, BK, Varadarajan, GS, Hathcock, TL, Smith, BF and Baker, HJ (2004). An inversion of 25 base pairs causes feline GM2 gangliosidosis variant. Exp Neurol 187: 30-37. (Pubitemid 38470009)
12. Rattazzi, MC, Appel, AM and Baker, HJ (1982). Enzyme replacement in feline GM2 gangliosidosis: catabolic effects of human beta-hexosaminidase A. Prog Clin Biol Res 94: 213-220.
13. Rattazzi, MC, Appel, AM, Baker, HJ and Nester, JA (1981). Towards enzyme replacement in GM2 gangliosidosis: inhibition of hepatic uptake and induction of CNS uptake of human beta-hexosaminidase in the cat. In: Callahan, JW and Lowden, JA (eds). Lysosomes and Lysosomal Storage Diseases. Raven Press: New York, NY. pp. 213-220.
14. Walkley, SU, Baker, HJ, Rattazzi, MC, Haskins, ME and Wu, JY (1991). Neuroaxonal dystrophy in neuronal storage disorders: evidence for major GABAergic neuron involvement. J Neurol Sci 104: 1-8.
15. Wood, PA, McBride, MR, Baker, HJ and Christian, ST (1985). Fluorescence polarization analysis, lipid composition, and Na+, K+-ATPase kinetics of synaptosomal membranes in feline GM1 and GM2 gangliosidosis. J Neurochem 44: 947-956. (Pubitemid 15110065)
16. Walkley, SU, Baker, HJ and Rattazzi, MC (1990). Initiation and growth of ectopic neurites and meganeurites during postnatal cortical development in ganglioside storage disease. Brain Res Dev Brain Res 51: 167-178. (Pubitemid 20056155)
17. Walkley, SU, Wurzelmann, S, Rattazzi, MC and Baker, HJ (1990). Distribution of ectopic neurite growth and other geometrical distortions of CNS neurons in feline GM2 gangliosidosis. Brain Res 510: 63-73. (Pubitemid 20060803)
18. Baek, RC, Martin, DR, Cox, NR and Seyfried, TN (2009). Comparative analysis of brain lipids in mice, cats, and humans with Sandhoff disease. Lipids 44: 197-205.
19. Passini, MA, Bu, J, Fidler, JA, Ziegler, RJ, Foley, JW, Dodge, JC et al. (2007). Combination brain and systemic injections of AAV provide maximal functional and survival benefts in the Niemann-Pick mouse. Proc Natl Acad Sci USA 104: 9505-9510. (Pubitemid 47185809)
20. Jacobs, F, Snoeys, J, Feng, Y, Van Craeyveld, E, Lievens, J, Armentano, D et al. (2008). Direct comparison of hepatocyte-specifc expression cassettes following adenoviral and nonviral hydrodynamic gene transfer. Gene Ther 15: 594-603.
21. Cox, NR, Ewald, SJ, Morrison, NE, Gentry, AS, Schuler, M and Baker, HJ (1998). Thymic alterations in feline GM1 gangliosidosis. Vet Immunol Immunopathol 63: 335-353. (Pubitemid 28446300)
22. Zhou, J, Cox, NR, Ewald, SJ, Morrison, NE and Basker, HJ (1998). Evaluation of GM1 ganglioside-mediated apoptosis in feline thymocytes. Vet Immunol Immunopathol 66: 25-42. (Pubitemid 28535467)
23. Zhou, J, Shao, H, Cox, NR, Baker, HJ and Ewald, SJ (1998). Gangliosides enhance apoptosis of thymocytes. Cell Immunol 183: 90-98. (Pubitemid 28222264)
24. Kanzaki, S, Yamaguchi, A, Yamaguchi, K, Kojima, Y, Suzuki, K, Koumitsu, N et al. (2010). Thymic alterations in GM2 gangliosidoses model mice. PLoS ONE 5 (8): e12105.
25. Matsuoka, K, Tsuji, D, Taki, T and Itoh, K (2011). Thymic involution and corticosterone level in Sandhoff disease model mice: new aspects the pathogenesis of GM2 gangliosidosis. J Inherit Metab Dis 34: 1061-1068.
26. Ciron, C, Cressant, A, Roux, F, Raoul, S, Cherel, Y, Hantraye, P et al. (2009). Human alpha-iduronidase gene transfer mediated by adeno-associated virus types 1, 2, and 5 in the brain of nonhuman primates: vector diffusion and biodistribution. Hum Gene Ther 20: 350-360.
27. Sondhi, D, Hackett, NR, Peterson, DA, Stratton, J, Baad, M, Travis, KM et al. (2007). Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Mol Ther 15: 481-491.
28. Cabrera-Salazar, MA, Roskelley, EM, Bu, J, Hodges, BL, Yew, N, Dodge, JC et al. (2007). Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease. Mol Ther 15: 1782-1788. (Pubitemid 47434184)
29. Vite, CH, McGowan, JC, Niogi, SN, Passini, MA, Drobatz, KJ, Haskins, ME et al. (2005). Effective gene therapy for an inherited CNS disease in a large animal model. Ann Neurol 57: 355-364. (Pubitemid 40343957)
30. Mays, LE and Wilson, JM (2011). The complex and evolving story of T cell activation to AAV vector-encoded transgene products. Mol Ther 19: 16-27.
31. Klein, RL, Dayton, RD, Leidenheimer, NJ, Jansen, K, Golde, TE and Zweig, RM (2006). Effcient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fuorescent proteins. Mol Ther 13: 517-527. (Pubitemid 43257619)
32. Georgievska, B, Kirik, D and Björklund, A (2002). Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp Neurol 177: 461-474. (Pubitemid 35366135)
33. Shapiro, BE, Logigian, EL, Kolodny, EH and Pastores, GM (2008). Late-onset Tay-Sachs disease: the spectrum of peripheral neuropathy in 30 affected patients. Muscle Nerve 38: 1012-1015.
34. Muldoon, LL, Neuwelt, EA, Pagel, MA and Weiss, DL (1994). Characterization of the molecular defect in a feline model for type II GM2-gangliosidosis (Sandhoff disease). Am J Pathol 144: 1109-1118.
35. Hoover, DM and Lubkowski, J (2002). DNAWorks: an automated method for designing oligonucleotides for PCR-based gene synthesis. Nucleic Acids Res 30: e43.
36. Broekman, ML, Baek, RC, Comer, LA, Fernandez, JL, Seyfried, TN and Sena-Esteves, M (2007). Complete correction of enzymatic defciency and neurochemistry in the GM1-gangliosidosis mouse brain by neonatal adeno-associated virus-mediated gene delivery. Mol Ther 15: 30-37. (Pubitemid 46043646)
37. Matalon, R, Surendran, S, Rady, PL, Quast, MJ, Campbell, GA, Matalon, KM et al. (2003). Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease. Mol Ther 7(5 Pt 1): 580-587. (Pubitemid 36626237)
38. Broekman, ML, Comer, LA, Hyman, BT and Sena-Esteves, M (2006). Adeno-associated virus vectors serotyped with AAV8 capsid are more effcient than AAV-1 or-2 serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience 138: 501-510. (Pubitemid 43255560)
39. Baek, RC, Kasperzyk, JL, Platt, FM and Seyfried, TN (2008). N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice. Neurochem Int 52: 1125-1133.
40. Seyfried, TN, Yu, RK and Miyazawa, N (1982). Differential cellular enrichment of gangliosides in the mouse cerebellum: analysis using neurological mutants. J Neurochem 38: 551-559. (Pubitemid 12138716)
41. Kasperzyk, JL, El-Abbadi, MM, Hauser, EC, D'Azzo, A, Platt, FM and Seyfried, TN (2004). N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis. J Neurochem 89: 645-653. (Pubitemid 38534150)
42. Macala, LJ, Yu, RK and Ando, S (1983). Analysis of brain lipids by high performance thin-layer chromatography and densitometry. J Lipid Res 24: 1243-1250. (Pubitemid 14236574)
43. Seyfried, TN, Glaser, GH and Yu, RK (1978). Cerebral, cerebellar, and brain stem gangliosides in mice susceptible to audiogenic seizures. J Neurochem 31: 21-27. (Pubitemid 8390973)
44. Folch, J, Lees, M and Sloane Stanley, GH (1957). A simple method for the isolation and purifcation of total lipides from animal tissues. J Biol Chem 226: 497-509.
45. Kasperzyk, JL, d'Azzo, A, Platt, FM, Alroy, J and Seyfried, TN (2005). Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice. J Lipid Res 46: 744-751. (Pubitemid 43073284)
46. Ando, S, Chang, NC and Yu, RK (1978). High-performance thin-layer chromatography and densitometric determination of brain ganglioside compositions of several species. Anal Biochem 89: 437-450. (Pubitemid 9067266)
47. Martin, DR, Rigat, BA, Foureman, P, Varadarajan, GS, Hwang, M, Krum, BK et al. (2008). Molecular consequences of the pathogenic mutation in feline GM1 gangliosidosis. Mol Genet Metab 94: 212-221.
48. Bradbury, AM, Morrison, NE, Hwang, M, Cox, NR, Baker, HJ and Martin, DR (2009). Neurodegenerative lysosomal storage disease in European Burmese cats with hexosaminidase beta-subunit defciency. Mol Genet Metab 97: 53-59.
49. Lacorazza, HD and Jendoubi, M (1995). In situ assessment of beta-hexosaminidase activity. BioTechniques 19: 434-440.